DelMar Pharmaceuticals Inc (DMPI)

2.18
0.18 7.60
NASDAQ : Health Care
Prev Close 2.36
Open 2.43
Day Low/High 2.17 / 2.59
52 Wk Low/High 1.72 / 10.87
Volume 213.40K
Avg Volume 101.80K
Exchange NASDAQ
Shares Outstanding 13.46M
Market Cap 27.33M
EPS -0.30
P/E Ratio 2.39
Div & Yield N.A. (N.A)

Latest News

DelMar Pharmaceuticals Announces Dosing Of The First Patient In Phase Two Clinical Trial Of VAL-083 For MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Study is currently enrolling MGMT-unmethylated Avastin (bevacizumab)-naive recurrent GBM patients at the University of Texas MD Anderson Cancer Center

DelMar Pharmaceuticals And MD Anderson Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

DelMar Pharmaceuticals And MD Anderson Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Study will enroll 48 MGMT-unmethylated Avastin (bevacizumab)-naive recurrent GBM patients

DelMar Pharmaceuticals Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083

DelMar Pharmaceuticals Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083

DelMar now holds seven allowed United States patents and eight international patents with more than 100 additional patent filings from thirteen patent families representing patent claims covering VAL-083 to 2036

DelMar Pharmaceuticals Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting

DelMar Pharmaceuticals Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting

Proposed Pivotal Phase III Clinical Trial in bevacizumab-failed glioblastoma multiforme (GBM) to enroll 180 patients with target completion in well under two years

DelMar Pharmaceuticals Presents Data Supporting The Potential Of VAL-083 As A New Treatment For Ovarian Cancer At The 11th Biennial Ovarian Cancer Research Symposium

DelMar Pharmaceuticals Presents Data Supporting The Potential Of VAL-083 As A New Treatment For Ovarian Cancer At The 11th Biennial Ovarian Cancer Research Symposium

DelMar to work with advisors to confirm a clinical strategy with VAL-083 for the treatment of refractory ovarian cancer, either as a single-agent or in combination with other approved agents

DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer

DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer

- DelMar will hold a Business Update Call for Shareholders on Wednesday September 7, 2016 at 5 p.m. EDT -

DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016

DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016

- Company will also hold a Business Update Call for Shareholders on Wednesday September 7, 2016 at 5 p.m. EDT -

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's how to trade five stocks that are ready to break out and trade higher from current levels.

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

Biotech investors have not had much to cheer about in 2016.

Shares of DelMar End Lower on First Day of Trading

Shares of DelMar End Lower on First Day of Trading

DelMar Pharmaceuticals enjoyed a bit of good news this week after its shares were uplisted to the Nasdaq Capital Market this week.

DelMar Pharmaceuticals Announces Approval For Listing On NASDAQ

DelMar Pharmaceuticals Announces Approval For Listing On NASDAQ

DMPI to Begin Trading on NASDAQ Capital Market on July 12, 2016